Literature DB >> 9773435

0.25% chlorhexidine gluconate gel. A protective topical microbicide.

D L Patton1, Y T Sweeney, T L McKay, S M DeMers, A M Clark, L K Rabe, S L Hillier.   

Abstract

BACKGROUND AND OBJECTIVES: An estimated 4 million new cases of chlamydial infection occur each year. This experiment assessed the effects of a vaginally applied gel formulation of 0.25% chlorhexidine gluconate on chlamydial infection and on the vaginal ecosystem. STUDY
DESIGN: Twelve monkeys were treated with a single application of 0.25% chlorhexidine gluconate. These animals were assessed for changes in vaginal flora before and at 30 minutes, 1 day, and 2 days postapplication by microbiologic analysis. Cervical and vaginal tissues were assessed by colposcopy at each time point. Five monkeys received a single application of 0.25% chlorhexidine gluconate gel followed (30 minutes) by a cervical inoculation with Chlamydia trachomatis. Four monkeys were inoculated with Chlamydia only. Cervicovaginal tissues were assessed via modified colposcopy, vaginal swabs were collected for assessment of vaginal flora, and cervical swabs were collected for detection of Chlamydia (culture/ligase chain reaction) at baseline and days 1, 2, and 7 postinoculation.
RESULTS: Changes in vaginal flora were minimal in all monkeys. Application of 0.25% chlorhexidine gluconate did not affect adversely vaginal colonization by lactobacilli. All chlamydial infection control monkeys were infected, whereas none of the five monkeys pretreated with chlorhexidine gluconate were positive for C. trachomatis by culture or ligase chain reaction. Colposcopic observations remained largely unchanged in all groups.
CONCLUSIONS: A 0.25% chlorhexidine gluconate gel was protective against chlamydial infection in all animals tested, had no adverse effect on the vaginal flora, and had minimal effect on cervicovaginal tissues after a single application.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9773435     DOI: 10.1097/00007435-199809000-00007

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  5 in total

1.  A guide for standardizing colposcopic observations for the evaluation of topical microbicide products in the pigtailed macaque model.

Authors:  Dorothy L Patton
Journal:  J Med Primatol       Date:  2011-10-24       Impact factor: 0.667

2.  Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1.

Authors:  Shendra R Passic; Mary Lee Ferguson; Bradley J Catalone; Tina Kish-Catalone; Vladyslav Kholodovych; Wei Zhu; William Welsh; Robert Rando; Mary K Howett; Brian Wigdahl; Mohamed Labib; Fred C Krebs
Journal:  Biomed Pharmacother       Date:  2010-11-04       Impact factor: 6.529

3.  The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques.

Authors:  Alexander M Cole; Dorothy L Patton; Lisa C Rohan; Amy L Cole; Yvonne Cosgrove-Sweeney; Nicole A Rogers; Deena Ratner; Alexandra B Sassi; Carol Lackman-Smith; Patrick Tarwater; Bharat Ramratnam; Piotr Ruchala; Robert I Lehrer; Alan J Waring; Phalguni Gupta
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

4.  Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection.

Authors:  Nina Thakkar; Vanessa Pirrone; Shendra Passic; Wei Zhu; Vladyslav Kholodovych; William Welsh; Robert F Rando; Mohamed E Labib; Brian Wigdahl; Fred C Krebs
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

5.  Chlamydia caviae infection alters abundance but not composition of the guinea pig vaginal microbiota.

Authors:  Elizabeth Neuendorf; Pawel Gajer; Anne K Bowlin; Patricia X Marques; Bing Ma; Hongqiu Yang; Li Fu; Michael S Humphrys; Larry J Forney; Garry S A Myers; Patrik M Bavoil; Roger G Rank; Jacques Ravel
Journal:  Pathog Dis       Date:  2015-03-10       Impact factor: 3.166

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.